129,372 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Diversify Advisory Services LLC

Key Points

• Diversify Advisory Services LLC acquired 129,372 Compass Pathways shares worth approximately $1.5 million, representing about 0.09% of the company. Institutional investors collectively own 46.19% of CMPS.
• Compass Pathways shares opened at $11.18, compared with a one-year range of $4.88 to $15.87. The company reported a quarterly loss of $1.88 per share, missing the consensus estimate of a $0.39 loss.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $23.36, substantially above the reported share price.

Diversify Advisory Services LLC bought a new stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 129,372 shares of the company's stock, valued at approximately $1,503,000. Diversify Advisory Services LLC owned about 0.09% of Compass Pathways at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of CMPS. EverSource Wealth Advisors LLC boosted its stake in shares of Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock worth $26,000 after buying an additional 1,920 shares during the last quarter. WINTON GROUP Ltd increased its position in Compass Pathways by 20.1% during the second quarter. WINTON GROUP Ltd now owns 17,900 shares of the company's stock valued at $253,000 after acquiring an additional 3,000 shares during the last quarter. Ancora Advisors LLC purchased a new stake in Compass Pathways during the second quarter valued at $43,000. TD Waterhouse Canada Inc. lifted its holdings in Compass Pathways by 10.9% in the third quarter. TD Waterhouse Canada Inc. now owns 33,622 shares of the company's stock valued at $401,000 after acquiring an additional 3,316 shares during the period. Finally, North Star Investment Management Corp. lifted its holdings in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company's stock valued at $42,000 after acquiring an additional 7,000 shares during the period. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Performance

Shares of Compass Pathways stock opened at $11.18 on Friday. The company has a market capitalization of $1.55 billion, a PE ratio of -2.42 and a beta of 2.55. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The company has a 50-day simple moving average of $13.10 and a two-hundred day simple moving average of $11.87. Compass Pathways PLC Sponsored ADR has a one year low of $4.88 and a one year high of $15.87.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on CMPS shares. Wolfe Research reissued an "outperform" rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Wells Fargo & Company started coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an "equal weight" rating and a $13.00 price target for the company. B. Riley Financial increased their price objective on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. Finally, Stifel Nicolaus boosted their target price on shares of Compass Pathways from $14.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Compass Pathways has a consensus rating of "Moderate Buy" and a consensus target price of $23.36.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.